Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

Cornerstone Wealth Group LLC doubled down on Regeneron Pharmaceuticals, increasing its holdings by 114% in Q1. The fund now ...

Genetic testing company 23andMe never hit on a sustainable business model and went bankrupt. Now, it's being sold to a non-profit launched by the co-founder, delaying addressing data privacy concerns.

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was ...

Regeneron has launched a $200 million donation matching program to support Good Days’ Retinal Vascular and Neovascular ...

Respiratory syncytial virus (RSV) causes severe illness in millions of young children each year.1 Globally, it is estimated that over 100 000 children younger than 5 years die each year from RSV; 97% ...

Through this program, Regeneron has committed to matching donations at a one-to-one rate, up to a total of $200 million, for ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...